Post-market Safety Reassessment of Ulinastatin for Injection

• Status: Unknown status
• Trial end date: 2018-08-01
• Target enrollment: 0
• Participant gender: All

Summary

1. Investigate the application of ulinastatin(UTI) in real practice clinic.(eg:population character, usage and dosage, course of treatment,etc )

2. Analysis the incidence of adverse drug reactions /adverse events of ulinastatin, collect the main clinical manifestations, treatment, outcome, influence factors; provide evidence for improving the recommended medication plan of ulinastatin.

3. Evaluate the safety of ulinastatin , obtain scientific conclusion , and provide evidence for appropriate medication to administration department of health authority.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Techpool Bio-Pharma Co., Ltd.
• Collaborators: Center for ADR Monitoring of Guangdong; Center for Adverse Drug Reaction Monitoring of Guangdong
• Treatments: Trypsin Inhibitors; Urinastatin

Criteria

Inclusion Criteria:

• Patients with ulinastatin treated

Exclusion Criteria:

• Not applicable